Literature DB >> 3838188

Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease.

R Zittoun, A Audebert, B Hoerni, A Bernadou, M Krulik, J Rojouan, H Eghbali, H Merle-Béral, Y Parlier, J Diebold.   

Abstract

From 1976 to 1981, 335 patients with untreated Hodgkin's disease, clinical stages I, II, and IIIA, have been treated by MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) chemotherapy, three to six cycles according to the prognostic factors, combined with radiotherapy. Irradiation was always performed after the first three cycles of chemotherapy, and was randomized between extensive radiotherapy, ie, mantle and paraaortic areas for supradiaphragmatic presentations, and radiotherapy restricted to the involved areas. No significant difference was observed between the two randomized branches for the disease-free survival (86% after six years in the involved field branch v 90% in the extended field branch), and none for the overall survival. Most of the relapses occurred in nonirradiated areas in the first group, and in irradiated areas in the second. Relapses were especially frequent in the IIE stages with pulmonary extension; extranodal relapses occurred with osseous and cutaneous localizations. Two cases of secondary leukemia were observed after three- or six-cycle MOPP plus radiotherapy limited to the involved areas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838188     DOI: 10.1200/JCO.1985.3.2.207

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

Review 1.  Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Authors:  Joachim Yahalom
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 2.  Current therapies in Hodgkin's disease.

Authors:  K E Kogel; J W Sweetenham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-30       Impact factor: 9.236

Review 3.  Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Authors:  Ralph M Meyer; Richard T Hoppe
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

Review 4.  Early stage Hodgkin's disease in adults: which is the correct treatment?

Authors:  M Brada
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

Review 5.  First-line treatment of Hodgkin's lymphoma.

Authors:  Beate Klimm; Andreas Engert; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

6.  Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease. Early results in 100 consecutive patients. Pierre-et-Marie-Curie Group.

Authors:  B Hoerni; M B Orgerie; H Eghbali; C M Blanc; B David; J Rojouan; R Zittoun
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 7.  [Pathogenesis and therapy of Hodgkin lymphoma].

Authors:  H Tesch; H Bohlen; J Wolf; A Engert
Journal:  Med Klin (Munich)       Date:  1998-02-15

Review 8.  Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.

Authors:  J G Franklin; M D Paus; A Pluetschow; L Specht
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

9.  Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

Authors:  Ana C Xavier; Narendranath Epperla; Jeffrey W Taub; Luciano J Costa
Journal:  Am J Hematol       Date:  2017-11-21       Impact factor: 10.047

Review 10.  [Modern pharmacotherapy of Hodgkin disease].

Authors:  A Josting; K Behringer; A Engert; V Diehl
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.